Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 673 of 5804
-
Wrist zap may tame tics: electrical pulses tested as Drug-Free option
Symptom relief CompletedTourette syndrome (TS) and chronic tic disorder (CTD) are neurodevelopmental disorders that impact approximately 1% of 5-18 year olds worldwide. Both TS and CTD are characterised by the presence of tics, which are repetitive, purposeless, movements or vocalisations of short durat…
Phase: NA • Sponsor: Nottingham University Hospitals NHS Trust • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Can a common schizophrenia drug curb violent acts? new trial aims to find out
Disease control Recruiting nowTwo-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs antipsychotic treatment as usual (TAU…
Phase: PHASE4 • Sponsor: New York State Psychiatric Institute • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for kids with psoriatic arthritis: apremilast trial begins
Disease control Recruiting nowThe study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could a new drug tame dangerous brain blood vessel clusters?
Disease control CompletedThis is a two-part, multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in participants with symptomatic cerebral cavernous malformation (CCM).
Phase: PHASE2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Double vision for heart stents: could two scans beat one?
Disease control OngoingThe COMBINE-INTERVENE Trial will investigate whether a PCI revascularization strategy based on combined FFR and OCT assessment is superior to a PCI revascularization strategy based on FFR-alone in patients with MVD with any presentation.
Phase: NA • Sponsor: Diagram B.V. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo approach tackles teen obesity: counseling plus pills
Disease control CompletedThe prevalence of adolescent severe obesity is at an all-time high in the United States and the refractory nature of this disease has led to a serious and challenging conundrum in terms of how to provide effective, safe, scalable, and durable treatments without placing undue stra…
Phase: PHASE2 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for rare skin Flare-Ups: drug offered to those with no options
Disease control CompletedThis Expanded Access Program in China is open to people with a serious skin disease called Generalized Pustular Psoriasis (GPP). This program provides a medicine called spesolimab to people with a GPP flare-up who have no alternative treatment options. This means that no therapy …
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug aims to slow kidney disease in IgA nephropathy patients
Disease control OngoingTo Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Primary Immunoglobulin A Nephropathy
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug combo aims to reboot immune system against lung cancer
Disease control OngoingThis phase II/III Lung-MAP trial studies how well immunotherapy treatment with N-803 (ALT-803) and pembrolizumab working in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). Natural killer cells, part of our immune system, a…
Phase: PHASE2, PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could a pill before IVF boost baby chances for endometriosis patients?
Disease control CompletedA Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-emb…
Phase: PHASE3 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New antibiotic may replace standard infection prevention in blood cancer patients
Prevention CompletedProphylaxis with fluoroquinolones in high-risk neutropenic patients is currently under scrutiny due to their toxicity and the potential of selecting multirresistant bacteria. In this setting, the search for an alternative prophylactic drug is a priority. The FOVOCIP study aimed t…
Phase: PHASE3 • Sponsor: Fundación para la Investigación Biosanitaria del Principado de Asturias • Aim: Prevention
Last updated Jun 27, 2026 13:01 UTC
-
New drug targets liver cancer by starving tumors of arginine
Disease control Recruiting nowEvaluate efficacy and safety of ADI-PEG 20 in patients with high-argininephenotypic and HCC
Phase: PHASE3 • Sponsor: Polaris Group • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Custom-Made vaccine shows promise in lymphoma fight
Disease control OngoingThis research study is studying a novel type of FL vaccine as a possible treatment for follicular lymphoma (FL). The agents involved in this study are: * Rituximab * Personalized NeoAntigen vaccine * Poly-ICLC * Pembrolizumab
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug cocktail aims to stop transplant rejection in blood cancer patients
Disease control Recruiting nowThis is a phase I-II clinical trial. Adult subjects with hematological malignancies undergoing allogeneic HSCT from an HLA matched sibling or ≥7 out of 8 allele level HLA matched unrelated donor are eligible for the study if they meet the criteria defined in our standard operatio…
Phase: PHASE1, PHASE2 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Nerve swap may restore movement in stroke-paralyzed arms
Disease control Recruiting nowThe purpose of this study is to evaluate the limb functional improvement after contralateral C7 root transfer in stroke patients.
Phase: NA • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug duo shows promise for tough cancers
Disease control CompletedPhase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) and AK117#AntiCD47 Antibody# combined with or without chemotherapy in advanced malignant tumors
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New PET scan may reveal if immunotherapy is working in melanoma
Disease control OngoingCombination treatment with nivolumab and ipilimumab before surgery may help people with melanoma because the drugs are designed to help the immune system target and destroy cancer cells (immunotherapy), which may shrink the cancer and prevent recurrence after surgery. Treatment g…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Hope for advanced breast cancer: new combo targets resistant tumors
Disease control OngoingThis study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Engineered immune cells take on liver cancer in new trial
Disease control Recruiting nowThis is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ECT204, an investigational ARTEMIS® T-cell therapy, in adult subjects with GPC3-positive hepatocellular carcinoma (HCC) who have experienced disease progression on, …
Phase: PHASE1, PHASE2 • Sponsor: Eureka Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New combo therapy aims to tame rare blood vessel disease
Disease control CompletedSystemic vasculitis are inflammatory diseases of the blood vessels, responsible for systemic manifestations. Among the systemic vasculitis affecting small blood vessels, IgA vasculitis (IgAV) is one of the most common forms and mainly affects the skin, joints, kidneys and gastroi…
Phase: PHASE3 • Sponsor: Hopital Foch • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC